Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO)
Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD)
The OASIS II trial is a multicentre, open label, randomized phase II trial. We will compare the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18 years and < 80 years of age).
Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085).
Potential synergism between Bruton's tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib, lenalidomide and rituximab (R2A) in patients with aggressive relapsed/refractory aggressive (R/R) B-cell non-Hodgkin lymphoma (NHL).
Roche announced data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrevuslizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection
Boston Scientific Corporation has completed enrolment in the EVOLVE II randomized, controlled clinical trial. The EVOLVE II trial is designed...
GSK and Theravance announced positive data from a Phase II study of the dual acting muscarinic antagonist and beta 2...
Amgen announces the results of a Phase II trial evaluating the safety and efficacy of Brodalumab (formerly AMG 827) in...
Novartis announced Phase II data showing AIN 457 (secukinumab) may significantly improve moderate-to-severe Plaque Psoriasis on the hands, feet and...